APA (7th ed.) Citation

Burman, W., Luczynski, P., Horsburgh, C. R., Phillips, P. P. J., & Johnston, J. (2025). Representativeness and adverse event reporting in late-phase clinical trials for rifampin-susceptible tuberculosis: A systematic review. Lancet Infectious Diseases, 25(2), e86. https://doi.org/10.1016/S1473-3099(24)00597-8

Chicago Style (17th ed.) Citation

Burman, William, Pauline Luczynski, C Robert Horsburgh, Patrick P J. Phillips, and James Johnston. "Representativeness and Adverse Event Reporting in Late-phase Clinical Trials for Rifampin-susceptible Tuberculosis: A Systematic Review." Lancet Infectious Diseases 25, no. 2 (2025): e86. https://doi.org/10.1016/S1473-3099(24)00597-8.

MLA (9th ed.) Citation

Burman, William, et al. "Representativeness and Adverse Event Reporting in Late-phase Clinical Trials for Rifampin-susceptible Tuberculosis: A Systematic Review." Lancet Infectious Diseases, vol. 25, no. 2, 2025, p. e86, https://doi.org/10.1016/S1473-3099(24)00597-8.